About Dr. Shen Nan
Dr. Shen Nan (沈南) is Chief Physician, Professor, and Director of the Division of Rheumatology at Renji Hospital, Shanghai Jiao Tong University School of Medicine, and one of China's most internationally recognized rheumatologists. She is a global authority on the genetics, immunopathogenesis, and precision treatment of systemic lupus erythematosus (SLE) and other systemic autoimmune diseases, with a research career that has produced landmark discoveries in lupus biology published in the world's leading scientific journals.
Dr. Shen leads one of Asia's most advanced lupus research and clinical programs, combining a high-volume specialist clinic with a world-class translational research laboratory. Her work on microRNA regulation of immune function in SLE, the genetic architecture of lupus in Asian populations, and biomarker-driven treatment stratification has been published in Nature, Nature Genetics, Nature Medicine, and other top-tier journals, establishing her as one of the most scientifically distinguished rheumatologists in the world.
Hospital Affiliation
Renji Hospital of Shanghai Jiao Tong University School of Medicine is one of China's top-ranked general hospitals with particular strength in rheumatology, immunology, and autoimmune disease. The Department of Rheumatology at Renji — co-led by Dr. Shen Nan and Professor Li Zhanguo — is consistently ranked among China's top rheumatology programs and manages one of the largest cohorts of SLE and systemic autoimmune disease patients in Asia. The department operates dedicated clinics for SLE, rheumatoid arthritis, Sjögren's syndrome, myositis, vasculitis, and antiphospholipid syndrome, with access to the full range of advanced biologic and targeted synthetic therapies.
Clinical Expertise
- Systemic lupus erythematosus (SLE) — diagnosis and disease activity assessment (SLEDAI); organ-specific manifestations (lupus nephritis, neuropsychiatric lupus, cardiopulmonary lupus); treatment optimization (hydroxychloroquine, corticosteroids, immunosuppressives, biologics including belimumab and anifrolumab); pregnancy and SLE; refractory SLE
- Lupus nephritis — kidney biopsy interpretation; induction and maintenance therapy; refractory lupus nephritis; voclosporin and belimumab combination therapy; monitoring and relapse prevention
- Sjögren's syndrome — primary and secondary Sjögren's; systemic manifestations; biologic therapy
- Inflammatory myopathies — dermatomyositis; polymyositis; anti-synthetase syndrome; immune-mediated necrotizing myopathy (IMNM)
- Systemic vasculitis — ANCA-associated vasculitis; Behçet's disease; IgA vasculitis
- Antiphospholipid syndrome (APS) — thrombotic APS; obstetric APS; catastrophic APS
- Precision rheumatology — biomarker-guided treatment selection; genetic risk stratification; treat-to-target strategies
Academic & Research Contributions
Dr. Shen Nan's research record is exceptional by any global standard. She has published landmark studies in Nature, Nature Genetics, Nature Medicine, Nature Communications, Annals of the Rheumatic Diseases, and Arthritis & Rheumatology, with a citation record that places her among the most influential rheumatology researchers in the world. Her discoveries on microRNA-146a regulation of innate immunity in SLE, the genetic loci associated with lupus susceptibility in Asian populations, and the role of neutrophil extracellular traps (NETs) in lupus pathogenesis have been widely cited and have opened new therapeutic avenues in autoimmune disease.
She has received China's National Science and Technology Progress Award and multiple other national and international honors. She serves on the editorial boards of leading rheumatology journals and is a frequent invited speaker at major international rheumatology conferences including ACR/ARHP and EULAR. She leads multiple national and international research programs on SLE genetics, biomarkers, and precision therapy.
Why International Patients Choose Dr. Shen Nan
Systemic lupus erythematosus is a complex, heterogeneous autoimmune disease that requires expert subspecialty management, particularly in patients with organ-threatening manifestations such as lupus nephritis, neuropsychiatric lupus, or refractory disease. Dr. Shen's clinic at Renji Hospital offers a level of lupus expertise — combining the world's most advanced research insights with high-volume clinical experience — that is genuinely unmatched in Asia and comparable to the world's leading lupus centers.
International patients commonly seek Dr. Shen's expertise for second opinions on SLE diagnosis and treatment strategy, optimization of therapy in refractory or treatment-resistant lupus, evaluation of complex organ manifestations, management of lupus in pregnancy, and access to cutting-edge biologic therapies that may not be available or affordable in their home countries.
What to Expect at Your Consultation
Consultations with Dr. Shen begin with a comprehensive rheumatological assessment including review of prior serology (ANA, anti-dsDNA, complement, antiphospholipid antibodies), organ function tests, imaging, kidney biopsy reports if available, and current medication history. CMCS will arrange certified translation of all prior medical records in advance. Dr. Shen will provide a definitive diagnostic and disease activity assessment, review the adequacy of current treatment, and outline an optimized management plan. A written English-language consultation summary is provided after every appointment.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides end-to-end support for international patients seeking rheumatology and lupus care with Dr. Shen Nan at Renji Hospital, including priority appointment scheduling, certified medical translation, pre-consultation record review, kidney biopsy coordination if required, and written English consultation summary. Contact us at contact@medicalsh.com, , or visit medicalsh.com.
0 commenti